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Purpose or Objective: Vaginal cuff brachytherapy with the 
dose prescribed at 0.5 cm depth from the applicator surface 
has been the standard treatment for gynaecological cancer 
patient after histerectomy for years. The implementation of 
computed tomography based (CT-based) plans caused 
changes in the standard approach in our hospital. We 
narrowed the planning target volume (PTV) in order to meet 
our in-house constraints requirement for organs at risk (OARs) 
in some cases. The aim of the study was to analyze doses at 
OARs in real adjusted image-based plans and in standard 0.5 
cm normalized plans. 
 
Material and Methods: Treatment plans of recent, 
consecutive 70 patients treated with high dose rate vaginal 
cuff CT-based brachytherapy were analyzed retrospectively. 
Dose normalization points and optimization methods were 
adjusted whenever standard approach wasn't suitable to 
meet all dose constraints for OARs (adjusted plan - AP). The 
second, standard treatment plan (SP) was created for every 
AP. APs were divided into three groups based on overdosage 
at definite OAR: Bladder Group (B group), Rectum Group (R 
group) and Bladder & Rectum Group (B&R group). Comparison 
of doses at the most exposed 0.1cc (D0.1cc) and 2cc (D2cc) 
of bladder and rectum between AP and SP was made in all 
three groups. 
 
Results: Vaginal cylinders of 10 to 35 mm radius were used. 
For 54% of all 70 cases the standard approach wasn't deemed 
suitable, and the treatment plan was adjusted (SP- 32 cases, 
AP-38 cases). 53% of the APs were assigned to the R group, 
21% to the B group and 26% to the B&R group. Mean values of 
rectum doses in R Group were 96.6% and 112.0% for RD0.1cc 
and 74.4% and 83.6% for RD2cc for AP and SP respectively. 
Mean values of bladder doses in B Group were 97.2% and 
108.0% for BD0.1cc and 79.3% and 86.9% for BD2cc for AP and 
SP respectively. In B&R Group mean values of RD0.1cc were 
93.1% and 108.9% and mean values of RD2cc were 71.8% and 
81.1% for AP and SP respectively, mean values of BD0.1cc 
were 94.4% and 105.9% and mean values of BD2cc were 77.5% 
and 84.4% for AP and SP respectively. The doses are 
presented as a percentage of prescribed dose. Dose 
differences between both plans in all three groups were 
statistically significant. 
 
Conclusion: Standard approach with dose points at 0.5 cm 
from the applicator surface is not suitable for all patients and 
can increase the risk of bladder or rectum complications. CT-
based plan allowing dose evaluation at OARs should be 
practiced on a daily basis. 
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Purpose or Objective: Brachytherapy has recently advanced 
towards personalized planning dosimetry with the 
commercial availability of image-based treatment planning 
systems for Ir-192. This marks an improvement over TG-43 
based planning dosimetry that relies on source specific data 
pre-calculated in a standard sized geometry of homogeneous 
water, hence disregarding patient-specific radiation scatter 
conditions and the radiological differences of tissue or 
applicator materials from water. The aim of this work is to 
perform a comparative study of the effect of these factors in 
Co-60 and Ir-192 HDR brachytherapy. 
 
Material and Methods: Ten clinical cases were studied for 
each of three disease cites considered (gynaecological, 
esophagus and breast). Two treatment plans were prepared 
for each case using the TG-43 option of a commercially 
available system (SagiPlan) with an Ir-192 (Ir2.A85-2) and a 
Co-60 (Co0.A86) HDR source. The plans were exported in 
dicom RT format. Corresponding personalized dosimetry data 
was obtained from Monte Carlo simulation using the MCNP6 
code. Monte Carlo input files were prepared automatically 
from the parsing of information in the dicom RT data using a 
custom software tool (BrachyGuide). Personalized and TG-43 
based dose distributions were compared in the 3D anatomical 
space of each patient using isodose distributions, % dose 
difference maps, Dose Volume Histograms and relevant 
indices of clinical interest. The statistical and clinical 
significance of differences between personalized and TG-43 
based dosimetry in Co-60 HDR brachytherapy was examined, 
and evaluated relative to corresponding results for Ir-192. 
 
Results: Results indicated that the effect of tissue 
heterogeneities and patient specific scatter conditions is less 
for Co-60 than for Ir-192 HDR treatments. In general, Co-60 
and Ir-192 sources of identical shape and construction have 
been found to deliver clinically comparable dose distributions 
despite definite differences in their physical characteristics. 
This is confirmed in terms of personalized dosimetry in this 
study. A lower dose to critical organs close to the target by 
Co-60 sources was observed along with a small increase in the 
overdose volume (V150 to V400). The choice of isotope was 
not found to have an impact on the prescribed dose. 
 
Conclusion: Co-60 may be used as an effective alternative to 
Ir-192 for HDR brachytherapy, producing similar plans of 
equivalent target coverage, but with a logistical benefit and 
without the need for an image based algorithm for 
personalized dosimetry.  
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Purpose or Objective: The dose delivered to the cervix 
HRCTV is often limited by OAR tolerances. A new applicator 
with shields in the anterior and posterior areas of the ovoids 
has been developed to try to reduce OAR doses. The current 
dose calculation formalism (TG43) calculates dose to water 
and does not take into account tissue heterogeneity. The 
Advanced Collapsed cone Engine (ACE) is the Elekta 
implementation of TG186; it models tissue heterogeneity and 
the effect of shielding. 
 
Material and Methods: Eleven patients were selected that 
had received CT/MR planned brachytherapy for cervical 
cancer using Elekta Fletcher tube and ovoids. The HRCTV and 
OARs had been outlined on the MR. For this study the 
applicator library was used to perform a best fit match of the 
shielded CT/MR Fletcher tube and ovoid model with the CT of 
the insertion. The shielded applicators have a slightly 
different geometry compared to the unshielded Fletcher 
applicators. The 25mm shielded ovoids were overlaid on 
35mm standard ovoids and 30mm shielded ovoids were 
overlaid on 40mm standard ovoids.  
The dwell positions, dwell weights and A points were 
maintained from the clinical plan. The plans were calculated 
